For patients with psoriasis (PsO), the implementation of effective medication regimens can be life changing. However, patients diagnosed with PsO are also at increased risk for the development of inflammatory bowel disease (IBD), including both ulcerative colitis and Crohn’s disease. Targeted anti-IL-17 therapies have demonstrated efficacy in the treatment of PsO but have been associated with either new or worsening IBD. It is imperative that clinicians treating patients with either isolated PsO or cooccurring PsO and IBD recognize which treatment options optimize efficacy and safety for patients in both groups.
In this CME Outfitters BriefCase, expert Dr. Anita Afzali will utilize case-based learning to illustrate the common features and pathophysiologic mechanisms underlying these two inflammatory disorders. Faculty will translate clinical data to help clinicians to select optimal treatments aimed at improving outcomes for patients impacted by PsO and IBD.